Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in nondiabetic rats

Figure 4 Effects of glucagon-like peptide-1 on the expression levels of genes associated with lipid metabolism in the liver and skeletal muscle. A: In the liver, there were no significant differences in the expression levels of sterol regulatory element-binding protein-1c (SREBP1c), fatty acid synthase (FAS), acetyl-CoA carboxylase-1 (ACC1), hormone-sensitive lipase (HSL), and apolipoprotein B (ApoB), carnitine palmitoyltransferase-1 (CPT1), long-chain acyl-CoA dehydrogenase (LCAD), or acyl-CoA oxidase 1 (ACOX1) among the three groups; B: In skeletal muscle, the expression of LPL was significantly greater in the high-fat diet (HFD)-Ex(+) group than in the control group. There were no significant differences in the expression levels of HSL, LPL, CPT1, LCAD, or ACOX1 between the HFD-Ex(-) and HFD-Ex(+) group. The fold changes were calculated as the ratio of the expression level in the HFD-Ex(+) or HFD-Ex(-) group to that in the control group. n = 8, ^aP < 0.05 between groups.